# An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

> **NCT03909295** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF)

## Interventions

- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT03909295
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-07
- **Primary completion:** 2019-11-19
- **Final completion:** 2019-11-19
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** This study was terminated early because the primary endpoint of PARAGON-HF was not met.
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03909295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03909295, "An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03909295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*